Opinion on Therapy Area in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Vernalis: Frovelan concerns a headache for shareholders

Published By Datamonitor
20 Sep 2001
CommentWire
CommentWire

Vernalis: benefiting from SB's regulatory headaches

Published By Datamonitor
14 Dec 2000
CommentWire
CommentWire

Vernalis/Endo: gain in menstrual migraine

New phase III data have confirmed previous results showing Vernalis and Endo's Frova to be an effective preventative treatment for menstrual migraine. This should pave the way for the migraine drug's approval in this additional indication. Anticipated in 2007, this approval is then expected to transform Frova's sales significantly.

Published By Datamonitor
08 May 2006
Expert View
Expert View

Vectibix's possible label expansion may only lead to a modest increase in uptake

Amgen has received a positive opinion from the CHMP for Vectibix in combination with chemotherapy in the first- and second-line treatment of mCRC. This is a significant step forward for Vectibix, but if it is approved, market competition will result in only a modest increase in uptake and commercial reward.

Published By Datamonitor
27 Jun 2011
CommentWire
CommentWire

Valeant/GlaxoSmithKline: side effects may jeopardize Trobalt's prospects

The first-in-class anti-epileptic drug Trobalt has received its first license after gaining European Commission approval as an adjunctive treatment for partial epilepsy. While Trobalt has shown impressive efficacy in a poorly managed patient population, its positioning in the treatment algorithm may be hindered by poor tolerability and a narrow label.

Published By Datamonitor
30 Mar 2011
Expert View
Expert View

Valeant/GlaxoSmithKline: Potiga's novel mechanism provides hope for drug-resistant epilepsy patients

The FDA has approved Potiga as an adjunctive treatment for partial-onset epilepsy in adults, the first potassium channel activator to receive approval for the treatment of epilepsy. While this novel drug will provide a useful treatment option for patients with drug-resistant epilepsy, its three times-daily dosing and high incidence of minor side effects will offset the benefits of efficacy.

Published By Datamonitor
14 Jun 2011
ResearchWire
ResearchWire

Vaccines: sales show global growth

Published By Datamonitor
17 Mar 2006
CommentWire
CommentWire

Vaccines: Intercell buys Iomai

Intercell has acquired Iomai for $189 million, in a deal motivated by the Austrian company's desire to gain ownership of Iomai's traveler's diarrhea vaccine and transdermal delivery technology. With the potential to deliver both vaccine and adjuvant, independently, through Iomai's transdermal patch, Intercell's development of its proprietary adjuvant IC31 may also benefit from the technology.

Published By Datamonitor
13 May 2008
CommentWire
CommentWire

Vaccines: further consolidation through Sanofi cash bid for Acambis

Sanofi Pasteur's offer, valuing Acambis at GBP276m, will give the French pharmaceutical firm extended access to Acambis's large vaccine pipeline, particularly to a universal influenza vaccine candidate and a Clostridium difficile vaccine. The acquisition represents a further important consolidation step in the growing vaccines market, leaving Austria's Intercell as the next big takeover target.

Published By Datamonitor
29 Jul 2008
Expert View
Expert View

Vaccines have re-emerged as growth drivers for the biopharmaceutical industry

Prior to 2000, vaccines were generally regarded as a commodity market with limited revenue opportunities. However, advances in vaccine technology, the launch of new vaccines, increased investment in research, a change of public opinion about vaccination, and more favorable legislation regarding vaccine injury compensation have contributed to their re-emergence as successful growth drivers.

Published By Datamonitor
01 Dec 2010

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.